PMV Pharmaceuticals (PMVP) Research & Development (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Research & Development came in at $15.3 million in Q1 2026, down 12.1% YoY from $17.4 million in Q1 2025, and down 3.14% on a QoQ basis from $15.8 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Research & Development (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Research & Development data on file, last reported at $15.3 million in Q1 2026.
- Quarterly Research & Development fell 12.1% year-over-year to $15.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.8 million (up 7.94% YoY) and the FY2025 annual result came in at $69.9 million, up 19.39% from the prior year.
- Research & Development slipped to $15.3 million in Q1 2026, from $15.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $18.4 million in Q2 2025 to a low of $11.5 million in Q2 2022.
- A 5-year average of $14.8 million and a median of $14.6 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 57.81% — and 2024, when it dropped 12.52%.
- Tracing PMVP's Research & Development over 5 years: stood at $15.0 million in 2022, then decreased by 10.94% to $13.4 million in 2023, then advanced by 2.88% to $13.8 million in 2024, then climbed by 14.96% to $15.8 million in 2025, then slipped by 3.14% to $15.3 million in 2026.
- The last three Research & Development figures came in at $15.3 million (Q1 2026), $15.8 million (Q4 2025), and $18.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | 14.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.33 Mn |
| Dec 31, 2025 | 15.83 Mn |
| Sep 30, 2025 | 18.21 Mn |
| Jun 30, 2025 | 18.40 Mn |
| Mar 31, 2025 | 17.44 Mn |
| Dec 31, 2024 | 13.77 Mn |
| Sep 30, 2024 | 16.95 Mn |
| Jun 30, 2024 | 14.63 Mn |
| Mar 31, 2024 | 13.19 Mn |
| Dec 31, 2023 | 13.38 Mn |
| Sep 30, 2023 | 13.59 Mn |
| Jun 30, 2023 | 13.84 Mn |
| Mar 31, 2023 | 15.07 Mn |
| Dec 31, 2022 | 15.03 Mn |
| Sep 30, 2022 | 13.67 Mn |
| Jun 30, 2022 | 11.46 Mn |
| Mar 31, 2022 | 11.84 Mn |
| Dec 31, 2021 | 12.17 Mn |
| Sep 30, 2021 | 9.16 Mn |
| Jun 30, 2021 | 7.66 Mn |